Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson's Disease

被引:42
作者
Haas, Stefan Jean-Pierre [1 ]
Zhou, Xiaolai [2 ,3 ]
Machado, Venissa [2 ,4 ,5 ]
Wree, Andreas [1 ]
Krieglstein, Kerstin [4 ]
Spittau, Bjoern [4 ]
机构
[1] Univ Rostock, Med Ctr, Inst Anat, D-18055 Rostock, Germany
[2] Univ Freiburg, Inst Anat & Cell Biol, Dept Mol Embryol, Hugstetter Str 55, D-79106 Freiburg, Germany
[3] Cornell Univ, Weill Inst Cell & Mol Biol, Dept Mol Biol & Genet, Ithaca, NY USA
[4] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Hugstetter Str 55, D-79106 Freiburg, Germany
[5] Univ Freiburg, Fac Biol, Hugstetter Str 55, D-79106 Freiburg, Germany
来源
FRONTIERS IN MOLECULAR NEUROSCIENCE | 2016年 / 9卷
关键词
6-OHDA; microglia; astrocytes; Tnfu; Tgf beta 1; GROWTH-FACTOR BETA-1; MICROGLIAL ACTIVATION; TIME-COURSE; 6-OHDA; SYSTEM; CELLS; NEURONS; NG2; MACROPHAGES; ASTROCYTES;
D O I
10.3389/fnmol.2016.00007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is a neurodegenerative disorder that is characterized by loss of midbrain dopaminergic (mDA) neurons in the substantia nigra (SN). Microgliamediated neuroinflammation has been described as a common hallmark of PD and is believed to further trigger the progression of neurodegenerative events. Injections of 6-hydroxydopamine (6-OHDA) are widely used to induce degeneration of mDA neurons in rodents as an attempt to mimic PD and to study neurodegeneration, neuroinflammation as well as potential therapeutic approaches. In the present study, we addressed microglia and astroglia reactivity in the SN and the caudatoputamen (CPu) after 6-0HDA injections into the medial forebrain bundle (MFB), and further analyzed the temporal and spatial expression patterns of pro-inflammatory and anti-inflammatory markers in this mouse model of PD. We provide evidence that activated microglia as well as neurons in the lesioned SN and CPu express Transforming growth factor beta 1 (Tgf beta 1), which overlaps with the downregulation of pro-inflammatory markers Tnfu, and iNos, and upregulation of anti-inflammatory markers Yrn /and Argl. Taken together, the data presented in this study suggest an important role for Tgf beta 1 as a lesion-associated factor that might be involved in regulating microglia activation states in the 6-OHDA mouse model of PD in order to prevent degeneration of uninjured neurons by microglia-mediated release of neurotoxic factors such as Info and nitric oxide (NO).
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat
    Penttinen, Anna-Maija
    Suleymanova, Ilida
    Albert, Katrina
    Anttila, Jenni
    Voutilainen, Merja H.
    Airavaara, Mikko
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2016, 94 (04) : 318 - 328
  • [22] Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease
    Grealish, Shane
    Mattsson, Bengt
    Draxler, Peter
    Bjorklund, Anders
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2010, 31 (12) : 2266 - 2278
  • [23] Growth/differentiation factor-15 deficiency compromises dopaminergic neuron survival and microglial response in the 6-hydroxydopamine mouse model of Parkinson's disease
    Machado, Venissa
    Haas, Stefan J. -P.
    Halbach, Oliver von Bohlen und
    Wree, Andreas
    Krieglstein, Kerstin
    Unsicker, Klaus
    Spittau, Bjeorn
    [J]. NEUROBIOLOGY OF DISEASE, 2016, 88 : 1 - 15
  • [24] Rho Kinase Inhibition by Fasudil in the Striatal 6-Hydroxydopamine Lesion Mouse Model of Parkinson Disease
    Tatenhorst, Lars
    Toenges, Lars
    Saal, Kim-Ann
    Koch, Jan C.
    Szego, Eva M.
    Baehr, Mathias
    Lingor, Paul
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2014, 73 (08) : 770 - 779
  • [25] Neuroprotective effect of bromelain in 6-hydroxydopamine induced in vitro model of Parkinson's disease
    Okkay, Irmak Ferah
    Okkay, Ufuk
    Cicek, Betul
    Yilmaz, Aysegul
    Yesilyurt, Fatma
    Mendil, Ali Sefa
    Hacimuftuoglu, Ahmet
    [J]. MOLECULAR BIOLOGY REPORTS, 2021, 48 (12) : 7711 - 7717
  • [26] Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease
    Allbutt, Haydn N.
    Henderson, Jasmine M.
    [J]. JOURNAL OF NEUROSCIENCE METHODS, 2007, 159 (02) : 195 - 202
  • [27] Neuroprotective effect of bromelain in 6-hydroxydopamine induced in vitro model of Parkinson’s disease
    Irmak Ferah Okkay
    Ufuk Okkay
    Betul Cicek
    Aysegul Yilmaz
    Fatma Yesilyurt
    Ali Sefa Mendil
    Ahmet Hacimuftuoglu
    [J]. Molecular Biology Reports, 2021, 48 : 7711 - 7717
  • [28] Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease
    Chen, Weizhao
    Zheng, Qiongping
    Huang, Qiaoying
    Ma, Shanshan
    Li, Mingtao
    Przedborski, Serge
    [J]. ELIFE, 2022, 11
  • [29] Synaptic zinc contributes to motor and cognitive deficits in 6-hydroxydopamine mouse models of Parkinson's disease
    Sikora, Joanna
    Kieffer, Brigitte L.
    Paoletti, Pierre
    Ouagazzal, Abdel-Mouttalib
    [J]. NEUROBIOLOGY OF DISEASE, 2020, 134
  • [30] Africanized Bee Venom (Apis mellifera Linnaeus): Neuroprotective Effects in a Parkinson's Disease Mouse Model Induced by 6-hydroxydopamine
    Dantas, Camila G.
    da Paixao, Ailma O.
    Nunes, Tassia L. G. M.
    Silva, Italo J. F.
    Lima, Bruno dos S.
    Araujo, Adriano A. S.
    de Albuquerque-Junior, Ricardo L. C.
    Gramacho, Katia P.
    Padilha, Francine F.
    da Costa, Luiz P.
    Severino, Patricia
    Cardoso, Juliana C.
    Souto, Eliana B.
    Gomes, Margarete Z.
    [J]. TOXICS, 2022, 10 (10)